Osteoporosis Therapeutics - A Global Market Perspective

NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Therapeutics - A Global Market Perspective

http://www.reportlinker.com/p0164234/Osteoporosis-Therapeutics---A-Global-Market-Perspective.html

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing a fracture.

These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

OSTEOPOROSIS THERAPEUTICS BMR-1034

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. OUTLOOK 4

3. INDUSTRY OVERVIEW 4

Osteoporosis Therapeutics: An Evolutionary Scan 4

"A Sketch of the Present Industry Scenario" 5

Facts & Figures: The Osteoporosis Primacy 5

Snapshots 5

Factors Influencing Demand 6

Competitive Landscape 6

Market Trends and Issues 8

Can New Treatments Beat the Gold Standard? 8

Oral Calcitonin Likely to Emerge as Wonder Drug 9

New Bisphosphonates Challenge Established Brands 10

Side Effects of HRT Fuel Natural Alternatives Sales 10

Bone Formation Drugs Augur New Prospects 10

Estrogen Replacement Therapy: Will Dosing Make a Difference? 12

Is Prevention Always Better Than Cure? 12

Peptide-Based Osteoporosis Therapy Gaining Ground 12

Polymorphism- A Potent Diagnostic Marker 12

Bisphosphonates - The Other Side 13

Efficacy of Evista Under the Scanner 14

4. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE 14

ERT Drugs 14

Ups and Downs in the ERT Market 14

Bisphosphonates 15

The leading Therapeutic Market 15

SERMs (Selective Estrogen Receptor Modulators) 15

Market Overview 15

Calcitonins 15

Market Overview 15

5. PRODUCT FACTS 16

Bisphosphonates 16

Hormone Replacement Therapy/ Estrogen Replacement Therapy 16

Estrogens 16

Estrogens/Progesterones 16

Calcitonins 17

Selective Estrogen Receptor Modulators (SERMs) 17

Other Therapeutics 17

6. MAJOR CLINICAL TRIALS/FINDINGS 17

7. CORPORATE DEVELOPMENTS 18

Schering-Plough Acquires Organon BioSciences 18

Faes Farma Signs Marketing Agreement with Roche and

GlaxoSmithKline 19

Alethia and Emerillon Collaborate on Osteoporosis Therapies 19

Ipsen Enters into Co-marketing Agreement with MSD 19

Unigene Enters into Agreement with Novartis 20

Pharming Group Granted Subsidies to Develop Osteoporosis Drugs 20

Procter & Gamble Terminates Nasal Spray Collaboration with

Nastech- Pharmaceutical 20

GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics 21

Radius Initiates Phase II Trials for BA058 21

Novartis and Nordic Initiate Phase III Clinical Trial of Oral

Salmon Calcitonin 21

Medivir Initiates First Human Trials for MIV-701 22

P&G Receives FDA Approval for New Dosage of Actonel 22

Takeda Introduces Benet® for Osteoporosis Treatment 22

Labtec Obtains Approval to Market Hormone Replacement Patch

in Europe 23

Wyeth Obtains Conditional Approval for Osteoporosis Drug from

FDA 23

Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval 23

Japanese Pharma Majors Receive Approval for Generic

Osteoporosis Drug 24

8. MAJOR PLAYERS 24

Eli Lilly and Company (US) 24

F.Hoffmann-La Roche Ltd (Switzerland) 25

Merck & Co., Inc. (US) 25

Novartis AG (Switzerland) 25

Novo Nordisk A/S (Denmark) 25

Organon 25

Procter & Gamble Pharmaceuticals Inc. (US) 26

Sanofi-Aventis SA (France) 26

Servier SA (France) 26

Solvay Pharmaceuticals Inc. (US) 26

Unigene Laboratories, Inc. (US) 26

Wyeth (US) 27

9. GLOBAL MARKET ANALYTICS 27

10. THE UNITED STATES 32

Industry Overview 32

Osteoporosis in the US: An Insight 32

Osteoporosis - An Underserved Market? 32

Osteoporosis Prescription Market 33

Competitive Scenario 34

Competitive Review by Segment 34

Bisphosphonates 34

SERMs 35

Calcitonins 36

PTH Therapy 36

11. JAPAN 37

12. EUROPE 38

a. France 42

b. Germany 43

c. The United Kingdom 44

d. Italy 45

e. Spain 46

f. Rest of Europe 47

13. REST OF WORLD 48

Prevalence of Osteoporosis in Various Region-At a Glance 48

Korea 48

China 48

EXHIBITS

Table 1: Prevalence of Osteoporosis and Osteopenia in Major

Markets Worldwide - 2008 & 2013

Table 2: Percentage Breakdown of Leading Players in the Global

Osteoporosis Market - 2006

Table 3: Leading Osteoporosis Drugs Worldwide by Dollar Sales -

2006

Table 4: Leading Osteoporosis Therapies and its Cost per Day

Table 5: Global Osteoporosis Therapeutics Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 6: Percentage Breakdown of Global Osteoporosis

Therapeutics Market by Region for the Years 2008 & 2012

Table 7: Global Bisphosphonates Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Bisphosphonates Market

by Region for the Years 2008 & 2012

Table 9: Global ERT Drugs Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global ERT Drugs Market by

Region for the Years 2008 & 2012

Table 11: Global SERM Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 12: Percentage Breakdown of Global SERM Market by Region

for the Years 2008 & 2012

Table 13: Global Calcitonins Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 14: Percentage Breakdown of Global Calcitonins Market by

Region for the Years 2008 & 2012

Table 15: Market Shares of Leading Osteoporosis Drugs in the

US -2006

Table 16: Market Shares of Leading Players in the US

Osteoporosis Market - 2004

Table 17: Market Shares of Leading Players in the US

Bisphosphonates Market - 2004

Table 18: Osteoporosis Therapeutics Market by Product Group in

the US: 2007-2015 (Sales in US$ Million)

Table 19: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in the US for the Years 2008 & 2012

Table 20: Osteoporosis Therapeutics Market by Product Group in

Japan: 2007-2015 (Sales in US$ Million)

Table 21: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Japan for the Years 2008 & 2012

Table 22: Market Shares of Leading Players in the European

Market for Osteoporosis Therapeutics (2005)

Table 23: Osteoporosis Therapeutics Market by Region in

Europe: 2007-2015 (Sales in US$ Million)

Table 24: Percentage Breakdown of Osteoporosis Therapeutics

Market by Region in Europe for the Years 2008 & 2012

Table 25: Osteoporosis Therapeutics Market by Product Group in

Europe: 2007-2015 (Sales in US$ Million)

Table 26: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Europe for the Years 2008 & 2012

Table 27: Osteoporosis Therapeutics Market by Product Group in

France: 2007-2015 (Sales in US$ Million)

Table 28: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in France for the Years 2008 & 2012

Table 29: Osteoporosis Therapeutics Market by Product Group in

Germany: 2007-2015 (Sales in US$ Million)

Table 30: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Germany for the Years 2008 & 2012

Table 31: Osteoporosis Therapeutics Market by Product Group in

The UK: 2007-2015 (Sales in US$ Million)

Table 32: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in The UK for the Years 2008 & 2012

Table 33: Osteoporosis Therapeutics Market by Product Group in

Italy: 2007-2015 (Sales in US$ Million)

Table 34: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Italy for the Years 2008 & 2012

Table 35: Osteoporosis Therapeutics Market by Product Group in

Spain: 2007-2015 (Sales in US$ Million)

Table 36: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Spain for the Years 2008 & 2012

Table 37: Osteoporosis Therapeutics Market by Product Group in

Rest of Europe: 2007-2015 (Sales in US$ Million)

Table 38: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Rest of Europe for the Years 2008

& 2012

Table 39: Percentage Breakdown of Leading Brands in the Korean

Osteoporosis Therapeutics Market - 2005

Table 40: Osteoporosis Therapeutics Market by Product Group in

Rest of World: 2007-2015 (Sales in US$ Million)

Table 41: Percentage Breakdown of Osteoporosis Therapeutics

Market by Product Group in Rest of World for the Years 2008

& 2012

COMPANIES PROFILED

To order this report:

Therapy Industry: Osteoporosis Therapeutics - A Global Market Perspective

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo